Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye

Area of Science:

• Ophthalmology
• Gene Therapy
• Molecular Biology

Background:

• Pathological vessel growth in the eye can lead to vision impairment and blindness.
• Anti-angiogenic gene therapy is a potential strategy to combat ocular neovascularization.
• Various viral vectors, including adeno-associated virus (AAV) serotypes, adenovirus, and lentivirus, have been explored for ocular gene delivery.

Purpose of the Study:

• To review the current status and potential of anti-angiogenic gene therapy for ocular neovascularization.
• To evaluate the safety and efficacy of different viral vector systems in preclinical and clinical settings.
• To identify challenges and future directions for advancing ocular gene therapy.

Main Methods:

• Review of preclinical studies using viral vectors for anti-angiogenic gene therapy in ocular models.
• Analysis of clinical trial data for intraocular gene therapy targeting neovascularization.
• Investigation of therapeutic strategies focused on inhibiting vascular endothelial growth factors (VEGF) and other pro-angiogenic factors.

Main Results:

• Preclinical studies demonstrate the promise of gene therapy in controlling pathological angiogenesis.
• Clinical trials indicate that intraocular gene therapy for neovascularization is safe, with no severe adverse events or systemic toxicity.
• Current clinical studies have progressed up to Phase 2, showing therapeutic potential but requiring further investigation.

Conclusions:

• Anti-angiogenic gene therapy holds significant potential for treating vision-threatening ocular neovascularization.
• Viral vector-based gene therapy has proven safe in human trials for ocular conditions.
• Further clinical development, likely beyond Phase 2, is necessary to establish the long-term efficacy and broader application of this therapeutic approach.